A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Study name | Risk ratio [95% CI] | RR Point estimate | Weight in random-effects model | Percent of mortality from measles | Percent of mortality from diarrhea | Percent of mortality from measles + diarrhea | Percent of mortality from nutritional deficiencies | Percent of mortality from infectious diseases | Baseline / control group VAD prevalence estimate in population studied | What would GiveWell predict for the effect size, given our model and these inputs? | VAD prevalence estimate sources | VAD prevalence estimate notes (see note on previous cell for sources) | |||||||||||||||||||
2 | Agarwal 1995 | 1.22 [0.66, 2.25] | 1.22 | 4.0% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 62.5% | 0.78 | Agarwal 1995; Stevens et al. 2015, WHO Global Prevalence of Vitamin A Deficiency 1995 | Agarwal 1995 found that 3.2% of children participating in the study were diagnosed with xerophthalmia (see note on previous cell). Stevens et al. 2015 estimates that the prevalence of VAD among preschool-aged children in South Asia in 1991 was 47% (95% CI 14–78). Based on the relatively high xerophthalmia rates found among trial participants (see classification of xerophthalmia prevalence on Table 5, Pg. 9 of WHO Global Prevalence of Vitamin A Deficiency 1995), we roughly guess that VAD rates were halfway between Stevens et al. 2015's point estimate and upper bound for the prevalence of VAD among preschool-aged children in South Asia in 1991 (see cell formula). | |||||||||||||||||||
3 | Barreto 1994 | 1.00 [0.14, 7.08] | 1.00 | 0.5% | 0.01% | 28.39% | 28.40% | 9.47% | 54.77% | 54.7% | 0.82 | WHO Global Prevalence of Vitamin A Deficiency 1995 | The survey referenced in WHO Global Prevalence of Vitamin A Deficiency 1995 took place in 1989, and took place in the same region of Brazil as the VAS trial. It is not clear whether the children sampled for the VAD survey later participated in the VAS trial. We have not viewed documents on the original survey or investigated its methodology. | |||||||||||||||||||
4 | Benn 1997 | 0.46 [0.14, 1.47] | 0.46 | 1.4% | 23.61% | 17.16% | 40.77% | 6.45% | 80.24% | 45% | 0.78 | Benn et al. 1997; WHO Global Prevalence of Vitamin A Deficiency 1995; Stevens et al. 2015 | Benn et al. 1997 reports that no cases of xerophthalmia among program participants at baseline were found. WHO Global Prevalence of Vitamin A Deficiency 1995 does not include any data on Guinea-Bissau, but notes "VAD likely." We use the point estimate from Stevens et al. 2015 of the prevalence of VAD among preschool-aged children in sub-Saharan Africa in 1991 as our estimate. | |||||||||||||||||||
5 | Chowdhury 2002 | 0.14 [0.03, 0.63] | 0.14 | 0.9% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 47% | 0.83 | Stevens et al. 2015 | We have not been able to find a full paper on Chowdhury et al. 2002. We use Stevens et al. 2015's point estimate for the prevalence of VAD in South Asia in 1991 as our estimate. | |||||||||||||||||||
6 | Daulaire 1992 | 0.74 [0.55, 0.99] | 0.74 | 8.9% | 14.59% | 18.92% | 33.51% | 10.14% | 77.41% | 78% | 0.68 | Daulaire et al. 1992; Stevens et al. 2015. | Daulaire et al. 1992 reports a very high rate of xerophthalmia in the region. We have used the high-end estimate for VAD prevalence in South Asia in 1991 from Stevens et al. 2015 as our estimate. | |||||||||||||||||||
7 | DEVTA trial 2013 | 0.96 [0.89, 1.03] | 0.96 | 13.6% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 64.8% | 0.77 | DEVTA trial 2013 | DEVTA reports that 64.8% of children in the control group who underwent biomedical visits were VAD (retinol <0.70 μmol/L) and 13.3% were severely VAD (retinol <0.35 μmol/L). | |||||||||||||||||||
8 | Dibley 1996 | 0.33 [0.01, 7.99] | 0.33 | 0.2% | 14.03% | 20.93% | 34.96% | 2.81% | 74.01% | 56.8% | 0.76 | Dibley 1996 | Measured prevalence of VAD (serum retinol concentrations <0.70μmol/L) among placebo group participants. | |||||||||||||||||||
9 | Donnen 1998 | 0.60 [0.23, 1.55] | 0.60 | 2.0% | 8.50% | 9.57% | 18.07% | 5.08% | 80.84% | 70.9% | 0.81 | Donnen 1998 | Measured prevalence of VAD (serum retinol concentrations <0.70μmol/L) among control group participants at baseline. | |||||||||||||||||||
10 | Fisker 2014 | 0.93 [0.66, 1.31] | 0.93 | 7.9% | 23.61% | 17.16% | 40.77% | 6.45% | 80.24% | 54.7% | 0.74 | WHO, Global prevalence of vitamin A deficiency in populations at risk 1995–2005, 2009 | We use WHO's estimate of the prevalence of VAD among preschool-aged children in Guinea-Bissau, 1995-2005. | |||||||||||||||||||
11 | Herrera 1992 | 1.06 [0.82, 1.37] | 1.06 | 9.8% | 24.54% | 16.73% | 41.27% | 3.44% | 64.93% | 53% | 0.75 | Herrera 1992; Stevens et al. 2015, WHO Global Prevalence of Vitamin A Deficiency 1995 | Herrera et al. 1992 reports that 3% of preschool-aged children initially enrolled were diagnosed with xerophthalmia. Stevens et al. 2015 estimates that the prevalence of VAD among preschool-aged children in Sub-Saharan Africa in 1991 was 45% (95% CI 29–60). Based on the relatively high xerophthalmia rates found among trial participants (see classification of xerophthalmia prevalence on Table 5, Pg. 9 of WHO Global Prevalence of Vitamin A Deficiency 1995), we roughly guess that VAD rates were halfway between Stevens et al. 2015's point estimate and upper bound for the prevalence of VAD among preschool-aged children in sub-Saharan Africa in 1991 (see cell formula). | |||||||||||||||||||
12 | Pant 1996 | 0.57 [0.37, 0.88] | 0.57 | 6.2% | 14.59% | 18.92% | 33.51% | 10.14% | 77.41% | 47% | 0.81 | Stevens et al. 2015 | No information on baseline or control group rates of xerophthalmia or serum retinol concentrations available in Pant 1996. No serum retinol surveys from Nepal reported in WHO Global Prevalence of Vitamin A Deficiency 1995. We use the point estimate for the prevalence of VAD among preschool-aged children in South Asia in 1991 from Stevens et al. 2015 as our estimate. | |||||||||||||||||||
13 | Rahmathullah 1990 | 0.46 [0.30, 0.71] | 0.46 | 6.3% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 47% | 0.83 | Stevens et al. 2015 | No information on baseline or control group rates of xerophthalmia or serum retinol concentrations available in Rahmathullah 1990. Rahmathullah 1990 does not state when the trial took place, but we would guess it occurred in the late 1980s. We use the point estimate for the prevalence of VAD among preschool-aged children in South Asia in 1991 from Stevens et al. 2015 as our estimate. | |||||||||||||||||||
14 | Ross 1993 HEALTH | 0.30 [0.12, 0.74] | 0.30 | 2.1% | 10.62% | 33.61% | 44.23% | 6.56% | 83.79% | 73% | 0.62 | Ross et al. 1993 | Ross et al 1993 reports measuring serum retinol levels at baseline. | |||||||||||||||||||
15 | Ross 1993 SURVIVAL | 0.81 [0.67, 0.97] | 0.81 | 11.5% | 10.62% | 33.61% | 44.23% | 6.56% | 83.79% | 57% | 0.70 | Ross et al. 1993 | Ross et al 1993 reports measuring serum retinol levels at baseline. | |||||||||||||||||||
16 | Sommer 1986 | 0.73 [0.54, 1.00] | 0.73 | 8.7% | 7.63% | 17.78% | 25.41% | 5.57% | 64.57% | 60% | 0.81 | Sommer et al. 1986 | We have not seen any data on rates of vitamin A deficiency in Indonesia in the early 1980s. Given a high rate of xerophthalmia, we roughly guess that VAD rates may have been around 60%. | |||||||||||||||||||
17 | Venkatarao 1996 | 0.37 [0.10, 1.37] | 0.37 | 1.1% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 47% | 0.83 | Stevens et al. 2015 | No information on baseline or control group rates of xerophthalmia or serum retinol concentrations available in Venkatarao 1990. We use the point estimate for the prevalence of VAD among preschool-aged children in South Asia in 1991 from Stevens et al. 2015 as our estimate. | |||||||||||||||||||
18 | Vijayaraghavan 1990 | 1.02 [0.57, 1.82] | 1.02 | 4.3% | 9.51% | 18.50% | 28.01% | 11.48% | 74.28% | 47% | 0.83 | Stevens et al. 2015 | No information on baseline or control group rates of xerophthalmia or serum retinol concentrations available in Vijayaraghavan 1990. We use the point estimate for the prevalence of VAD among preschool-aged children in South Asia in 1991 from Stevens et al. 2015 as our estimate. | |||||||||||||||||||
19 | West 1991 | 0.70 [0.56, 0.88] | 0.70 | 10.5% | 14.59% | 18.92% | 33.51% | 10.14% | 77.41% | 63% | 0.74 | Stevens et al. 2015, WHO Global Prevalence of Vitamin A Deficiency 1995 | West 1991 found that 3.0% of children participating in the study were diagnosed with xerophthalmia (see note on previous cell). Stevens et al. 2015 estimates that the prevalence of VAD among preschool-aged children in South Asia in 1991 was 47% (95% CI 14–78). Based on the relatively high xerophthalmia rates found among trial participants (see classification of xerophthalmia prevalence on Table 5, Pg. 9 of WHO Global Prevalence of Vitamin A Deficiency 1995), we roughly guess that VAD rates were halfway between Stevens et al. 2015's point estimate and upper bound for the prevalence of VAD among preschool-aged children in South Asia in 1991 (see cell formula). | |||||||||||||||||||
20 | Lin 2008 | Not estimable | Not estimable | 0% | N/A | N/A | Lin 2008 has no weight in the meta-analysis, so we have not attempted to find information on baseline VAD rates. | |||||||||||||||||||||||||
21 | Overall-random effects | 13.51% | 20.16% | 33.67% | 8.53% | 75.13% | 58.92% | |||||||||||||||||||||||||
22 | ||||||||||||||||||||||||||||||||
23 | ||||||||||||||||||||||||||||||||
24 | ||||||||||||||||||||||||||||||||
25 | ||||||||||||||||||||||||||||||||
26 | ||||||||||||||||||||||||||||||||
27 | ||||||||||||||||||||||||||||||||
28 | ||||||||||||||||||||||||||||||||
29 | ||||||||||||||||||||||||||||||||
30 | ||||||||||||||||||||||||||||||||
31 | ||||||||||||||||||||||||||||||||
32 | ||||||||||||||||||||||||||||||||
33 | ||||||||||||||||||||||||||||||||
34 | ||||||||||||||||||||||||||||||||
35 | ||||||||||||||||||||||||||||||||
36 | ||||||||||||||||||||||||||||||||
37 | ||||||||||||||||||||||||||||||||
38 | ||||||||||||||||||||||||||||||||
39 | ||||||||||||||||||||||||||||||||
40 | ||||||||||||||||||||||||||||||||
41 | ||||||||||||||||||||||||||||||||
42 | ||||||||||||||||||||||||||||||||
43 | ||||||||||||||||||||||||||||||||
44 | ||||||||||||||||||||||||||||||||
45 | ||||||||||||||||||||||||||||||||
46 | ||||||||||||||||||||||||||||||||
47 | ||||||||||||||||||||||||||||||||
48 | ||||||||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||||||||
100 |